ImmunoPrecise Antibodies (NASDAQ:IPA – Get Rating) and Athenex (NASDAQ:ATNX – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, valuation, dividends and risk.
Valuation & Earnings
This table compares ImmunoPrecise Antibodies and Athenex’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|ImmunoPrecise Antibodies||$15.32 million||6.55||-$13.22 million||($0.68)||-5.94|
|Athenex||$120.18 million||0.97||-$199.77 million||($1.72)||-0.56|
ImmunoPrecise Antibodies has higher earnings, but lower revenue than Athenex. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Athenex, indicating that it is currently the more affordable of the two stocks.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings and target prices for ImmunoPrecise Antibodies and Athenex, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ImmunoPrecise Antibodies presently has a consensus price target of $12.00, suggesting a potential upside of 197.03%. Athenex has a consensus price target of $4.00, suggesting a potential upside of 318.85%. Given Athenex’s higher possible upside, analysts plainly believe Athenex is more favorable than ImmunoPrecise Antibodies.
Institutional and Insider Ownership
6.6% of ImmunoPrecise Antibodies shares are owned by institutional investors. Comparatively, 40.9% of Athenex shares are owned by institutional investors. 12.0% of Athenex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Risk and Volatility
ImmunoPrecise Antibodies has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Comparatively, Athenex has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500.
ImmunoPrecise Antibodies beats Athenex on 7 of the 13 factors compared between the two stocks.
About ImmunoPrecise Antibodies
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.
Receive News & Ratings for ImmunoPrecise Antibodies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoPrecise Antibodies and related companies with MarketBeat.com's FREE daily email newsletter.